Literature DB >> 24660610

Anti-breast cancer effects and mechanisms of Xihuang pill on human breast cancer cell lines.

Guofeng Pan, Wandan Wang, Lan Wang, Fangbo Zhang, Xiaojie Yin, Jianlu Wang, Rixin Liang.   

Abstract

OBJECTIVE: To investigate the anti-breast cancer (BC) effects and mechanisms of action of Xihuang pill (XHP) by conducting in vitro experiments on human BC cell lines.
METHODS: Two human BC cell lines (MCF-7 and MDA- MB231) were cultured and treated with XHP. Cell viability was detected using the 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. Flow cytometry was used to measure the cell cycle and apoptosis. The cell cycle was analyzed with propidium iodide staining. Apoptosis was evaluated using the Annexin V-fluorescein isothiocyanate/propidium iodide method. Western blotting was used to analyze the expression of estrogen receptor (ER)-alpha and ER-beta.
RESULTS: XHP had growth-inhibitory effects on MCF-7 and MDA-MB231 cells with a half-maximal inhibitory concentration (IC50) of 10.14 mg/mL (MCF-7) and 8.98 mg/mL (MDA-MB231). Apoptosis was induced to some extent. Certain changes in the ER were caused. Upregulation of ER-a protein was found in MCF-7 cells. ER-beta expression in MDA-MB231 cells was increased. Cell-cycle arrest was not observed in the two BC cell lines. ER-1 expression in MCF-7 cells was unchanged. No ER-a expression was shown in MDA-MB231 cells.
CONCLUSION: These data suggest that XHP can affect cell viability and cause apoptosis, but that the cell cycle is not blocked. XHP has a certain impact on ER expression, but its mechanisms of action of anti-BC effects may not be due to regulation of ER expression.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24660610     DOI: 10.1016/s0254-6272(14)60011-x

Source DB:  PubMed          Journal:  J Tradit Chin Med        ISSN: 0255-2922            Impact factor:   0.848


  8 in total

1.  Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell line.

Authors:  Wenxian Zheng; Shuyan Han; Shantong Jiang; Lina Pang; Xiaohong Li; Xijuan Liu; Minhua Cao; Pingping Li
Journal:  Biomed Rep       Date:  2016-09-30

2.  Clinical Effects of Xihuang Pill Combined with Chemotherapy in Patients with Advanced Colorectal Cancer.

Authors:  Dan Yu; Guang Yu An
Journal:  Evid Based Complement Alternat Med       Date:  2017-03-28       Impact factor: 2.629

3.  Antitumor effects of Xi Huang pills on MDA‑MB‑231 cells in vitro and in vivo.

Authors:  Wenxian Zheng; Shuyan Han; Shantong Jiang; Xiran He; Xiaohong Li; Huirong Ding; Minhua Cao; Pingping Li
Journal:  Mol Med Rep       Date:  2018-06-21       Impact factor: 2.952

Review 4.  Meta-Analysis of Xihuang Pill Efficacy When Combined with Chemotherapy for Treatment of Breast Cancer.

Authors:  Dan Mao; Lei Feng; Siqi Huang; Shaofan Zhang; Weijun Peng; Sifang Zhang
Journal:  Evid Based Complement Alternat Med       Date:  2019-03-12       Impact factor: 2.629

5.  Network Pharmacology-Based Strategy for Predicting Therapy Targets of Traditional Chinese Medicine Xihuang Pill on Liver Cancer.

Authors:  Xu Zhao; Jian Hao; Sinuan Chen
Journal:  Evid Based Complement Alternat Med       Date:  2020-03-14       Impact factor: 2.629

6.  Network Pharmacology-Oriented Identification of Key Proteins and Signaling Pathways Targeted by Xihuang Pill in the Treatment of Breast Cancer.

Authors:  Jiafa Wu; Dongping Luo; Shengnan Li
Journal:  Breast Cancer (Dove Med Press)       Date:  2020-12-08

7.  Native musk and synthetic musk ketone strongly induced the growth repression and the apoptosis of cancer cells.

Authors:  Ling Xu; Yi Cao
Journal:  BMC Complement Altern Med       Date:  2016-12-08       Impact factor: 3.659

8.  Xihuang Pill Induces Apoptosis of Human Glioblastoma U-87 MG Cells via Targeting ROS-Mediated Akt/mTOR/FOXO1 Pathway.

Authors:  Meng Shao; Zhenqiang He; Zhixin Yin; Peihong Ma; Qian Xiao; Yafeng Song; Ziming Huang; Yujie Ma; Yuqin Qiu; Aizhi Zhao; Taicheng Zhou; Qirui Wang
Journal:  Evid Based Complement Alternat Med       Date:  2018-06-26       Impact factor: 2.629

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.